메뉴 건너뛰기




Volumn 26, Issue 1, 2016, Pages 2-30

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up

Author keywords

Adjuvant; Consensus; Endometrial neoplasms; Practice guideline; Surgery; Treatment

Indexed keywords

CONSENSUS DEVELOPMENT; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; MEDICAL SOCIETY; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; STANDARDS;

EID: 84953332991     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000609     Document Type: Conference Paper
Times cited : (534)

References (211)
  • 2
    • 33847366564 scopus 로고    scopus 로고
    • Prognostic factors for uterine cancer in reproductive-aged women
    • Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109:655-662.
    • (2007) Obstet Gynecol , vol.109 , pp. 655-662
    • Lee, N.K.1    Cheung, M.K.2    Shin, J.Y.3
  • 3
    • 84953302182 scopus 로고    scopus 로고
    • National Cancer Institute (1 April 2015, date last accessed)
    • National Cancer Institute. Endometrial cancer treatment Physician Data Query (PDQ). 2015; http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/healthprofessional (1 April 2015, date last accessed).
    • (2015) Endometrial Cancer Treatment Physician Data Query (PDQ)
  • 4
    • 22544448651 scopus 로고    scopus 로고
    • ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists number 65 2005: Management of endometrial cancer
    • ACOG
    • ACOG. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106:413-425.
    • (2005) Obstet Gynecol , vol.106 , pp. 413-425
  • 5
    • 84877254190 scopus 로고    scopus 로고
    • Integrated genomic characterization of endometrial carcinoma
    • Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
    • (2013) Nature , vol.497 , pp. 67-73
    • Kandoth, C.1    Schultz, N.2    Cherniack, A.D.3
  • 6
    • 33746312861 scopus 로고    scopus 로고
    • Immunophenotypic diversity of endometrial adenocarcinomas: Implications for differential diagnosis
    • Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
    • (2006) Mod Pathol , vol.19 , pp. 1091-1100
    • Reid-Nicholson, M.1    Iyengar, P.2    Hummer, A.J.3
  • 7
    • 29744432124 scopus 로고    scopus 로고
    • Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma
    • Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006;106:87-94.
    • (2006) Cancer , vol.106 , pp. 87-94
    • Broaddus, R.R.1    Lynch, H.T.2    Chen, L.M.3
  • 8
    • 84885354186 scopus 로고    scopus 로고
    • Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi33-vi38.
    • (2013) Ann Oncol , vol.24 , pp. vi33-vi38
    • Colombo, N.1    Preti, E.2    Landoni, F.3
  • 9
    • 0035879607 scopus 로고    scopus 로고
    • Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients
    • Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2001;33:139-144.
    • (2001) Clin Infect Dis , vol.33 , pp. 139-144
    • Dykewicz, C.A.1
  • 10
    • 84953258809 scopus 로고    scopus 로고
    • World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report (2 April 2015, date last accessed)
    • World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Endometrial Cancer. 2013; http://www.dietandcancerreport.org (2 April 2015, date last accessed).
    • (2013) Food, Nutrition, Physical Activity, and the Prevention of Endometrial Cancer
  • 11
    • 84895540960 scopus 로고    scopus 로고
    • Endometrial carcinoma in women aged 40 years and younger
    • Garg K, Soslow RA. Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med. 2014;138:335-342.
    • (2014) Arch Pathol Lab Med , vol.138 , pp. 335-342
    • Garg, K.1    Soslow, R.A.2
  • 12
    • 84876787194 scopus 로고    scopus 로고
    • Metabolic syndrome and endometrial cancer: A meta-analysis
    • Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45:28-36.
    • (2014) Endocrine , vol.45 , pp. 28-36
    • Esposito, K.1    Chiodini, P.2    Capuano, A.3
  • 13
    • 84897847172 scopus 로고    scopus 로고
    • Overweight, obesity and endometrial cancer risk: Results from a systematic review and meta-analysis
    • Zhang Y, Liu H, Yang S, et al. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2014;29:e21-e29.
    • (2014) Int J Biol Markers , vol.29 , pp. e21-e29
    • Zhang, Y.1    Liu, H.2    Yang, S.3
  • 14
    • 79953295548 scopus 로고    scopus 로고
    • Metabolic syndrome and endometrial cancer risk
    • Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884-889.
    • (2011) Ann Oncol , vol.22 , pp. 884-889
    • Rosato, V.1    Zucchetto, A.2    Bosetti, C.3
  • 15
    • 84909997906 scopus 로고    scopus 로고
    • Association between diabetes, diabetes treatment and risk of developing endometrial cancer
    • Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111:1432-1439.
    • (2014) Br J Cancer , vol.111 , pp. 1432-1439
    • Luo, J.1    Beresford, S.2    Chen, C.3
  • 16
    • 84905082203 scopus 로고    scopus 로고
    • Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis
    • Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748-758.
    • (2014) Hum Reprod Update , vol.20 , pp. 748-758
    • Barry, J.A.1    Azizia, M.M.2    Hardiman, P.J.3
  • 17
    • 67349141286 scopus 로고    scopus 로고
    • Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship
    • Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114:121-127.
    • (2009) Gynecol Oncol , vol.114 , pp. 121-127
    • Fader, A.N.1    Arriba, L.N.2    Frasure, H.E.3    Von Gruenigen, V.E.4
  • 18
    • 84900387268 scopus 로고    scopus 로고
    • Reproductive factors and the risk of endometrial cancer
    • Ali AT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer. 2014;24:384-393.
    • (2014) Int J Gynecol Cancer , vol.24 , pp. 384-393
    • Ali, A.T.1
  • 20
    • 0026453702 scopus 로고
    • Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study
    • Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167:1317-1325.
    • (1992) Am J Obstet Gynecol , vol.167 , pp. 1317-1325
    • Brinton, L.A.1    Berman, M.L.2    Mortel, R.3
  • 21
    • 68649121618 scopus 로고    scopus 로고
    • Hormone-related factors and gynecological conditions in relation to endometrial cancer risk
    • Zucchetto A, Serraino D, Polesel J, et al. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev. 2009;18:316-321.
    • (2009) Eur J Cancer Prev , vol.18 , pp. 316-321
    • Zucchetto, A.1    Serraino, D.2    Polesel, J.3
  • 22
    • 0032537990 scopus 로고    scopus 로고
    • Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    • Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1371-1388
    • Fisher, B.1    Costantino, J.P.2    Wickerham, D.L.3
  • 23
    • 84925229366 scopus 로고    scopus 로고
    • Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions
    • Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136:3-7.
    • (2015) Gynecol Oncol , vol.136 , pp. 3-7
    • Lancaster, J.M.1    Powell, C.B.2    Chen, L.M.3    Richardson, D.L.4
  • 24
    • 58849114609 scopus 로고    scopus 로고
    • Cancer screening in the United States 2009: A review of current American Cancer Society guidelines and issues in cancer screening
    • Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27-41.
    • (2009) CA Cancer J Clin , vol.59 , pp. 27-41
    • Smith, R.A.1    Cokkinides, V.2    Brawley, O.W.3
  • 25
    • 78650687714 scopus 로고    scopus 로고
    • Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: A case-control study within the UKCTOCS cohort
    • Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12:38-48.
    • (2011) Lancet Oncol , vol.12 , pp. 38-48
    • Jacobs, I.1    Gentry-Maharaj, A.2    Burnell, M.3
  • 26
    • 84953302182 scopus 로고    scopus 로고
    • National Cancer Institute (2 April 2015, date last accessed)
    • National Cancer Institute. Endometrial Cancer Screening Physician Data Query (PDQ). 2015; www.cancer.gov/cancertopics/pdq/screening/endometrial/HealthProfessional/(2 April 2015, date last accessed).
    • (2015) Endometrial Cancer Screening Physician Data Query (PDQ)
  • 27
    • 84901391552 scopus 로고    scopus 로고
    • Committee Opinion 601: Tamoxifen and uterine cancer
    • ACOG
    • ACOG. Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123:1394-1397.
    • (2014) Obstet Gynecol , vol.123 , pp. 1394-1397
  • 28
    • 84912075615 scopus 로고    scopus 로고
    • Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: A meta-analysis
    • Fu Y, Zhuang Z. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol. 2014;7:6419-6429.
    • (2014) Int J Clin Exp Pathol , vol.7 , pp. 6419-6429
    • Fu, Y.1    Zhuang, Z.2
  • 29
    • 84877594960 scopus 로고    scopus 로고
    • Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)
    • Manchanda R, Saridogan E, Abdelraheim A, et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet. 2012;286:1555-1562.
    • (2012) Arch Gynecol Obstet , vol.286 , pp. 1555-1562
    • Manchanda, R.1    Saridogan, E.2    Abdelraheim, A.3
  • 30
    • 84876900933 scopus 로고    scopus 로고
    • Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts
    • Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812-823.
    • (2013) Gut , vol.62 , pp. 812-823
    • Vasen, H.F.1    Blanco, I.2    Aktan-Collan, K.3
  • 31
    • 0034755101 scopus 로고    scopus 로고
    • Endometrial cancer in women 40 years old or younger
    • Duska LR, Garrett A, Rueda BR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388-393.
    • (2001) Gynecol Oncol , vol.83 , pp. 388-393
    • Duska, L.R.1    Garrett, A.2    Rueda, B.R.3
  • 33
    • 84940930055 scopus 로고    scopus 로고
    • European society of gynecological oncology task force for fertility preservation: Clinical recommendations for fertility-sparing management in young endometrial cancer patients
    • Rodolakis A, Biliatis I, Morice P, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer. 2015;25:1258-1265.
    • (2015) Int J Gynecol Cancer , vol.25 , pp. 1258-1265
    • Rodolakis, A.1    Biliatis, I.2    Morice, P.3
  • 34
    • 62549137810 scopus 로고    scopus 로고
    • Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma
    • Leitao MM Jr, Kehoe S, Barakat RR, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2009;113:105-108.
    • (2009) Gynecol Oncol , vol.113 , pp. 105-108
    • Leitao, Jr.M.M.1    Kehoe, S.2    Barakat, R.R.3
  • 35
    • 34447579172 scopus 로고    scopus 로고
    • Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women
    • Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798-2803.
    • (2007) J Clin Oncol , vol.25 , pp. 2798-2803
    • Ushijima, K.1    Yahata, H.2    Yoshikawa, H.3
  • 36
    • 0032860063 scopus 로고    scopus 로고
    • Radiologic staging in patients with endometrial cancer: A meta-analysis
    • Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999;212:711-718.
    • (1999) Radiology , vol.212 , pp. 711-718
    • Kinkel, K.1    Kaji, Y.2    Yu, K.K.3
  • 37
    • 79952024674 scopus 로고    scopus 로고
    • Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women
    • Minig L, Franchi D, Boveri S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22:643-649.
    • (2011) Ann Oncol , vol.22 , pp. 643-649
    • Minig, L.1    Franchi, D.2    Boveri, S.3
  • 38
    • 84882455434 scopus 로고    scopus 로고
    • Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer
    • Kim MK, Seong SJ, Song T, et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol. 2013;130:470-473.
    • (2013) Gynecol Oncol , vol.130 , pp. 470-473
    • Kim, M.K.1    Seong, S.J.2    Song, T.3
  • 39
    • 84866846627 scopus 로고    scopus 로고
    • Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: A systematic review and metaanalysis
    • Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.e1-e12.
    • (2012) Am J Obstet Gynecol , vol.207 , Issue.266 , pp. e1-e12
    • Gallos, I.D.1    Yap, J.2    Rajkhowa, M.3
  • 40
    • 84873704819 scopus 로고    scopus 로고
    • Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)
    • Park JY, Kim DY, Kim JH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49:868-874.
    • (2013) Eur J Cancer , vol.49 , pp. 868-874
    • Park, J.Y.1    Kim, D.Y.2    Kim, J.H.3
  • 42
    • 79960681651 scopus 로고    scopus 로고
    • Fertility-sparing therapy in young women with endometrial cancer: 2010 update
    • Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer. 2010;20:1170-1187.
    • (2010) Int J Gynecol Cancer , vol.20 , pp. 1170-1187
    • Erkanli, S.1    Ayhan, A.2
  • 43
    • 34447335590 scopus 로고    scopus 로고
    • Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer
    • Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 2007;22:1953-1958.
    • (2007) Hum Reprod , vol.22 , pp. 1953-1958
    • Yamazawa, K.1    Hirai, M.2    Fujito, A.3
  • 44
    • 84894493540 scopus 로고    scopus 로고
    • Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: Systematic review and meta-analysis
    • Koskas M, Uzan J, Luton D, et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101:785-794.
    • (2014) Fertil Steril , vol.101 , pp. 785-794
    • Koskas, M.1    Uzan, J.2    Luton, D.3
  • 45
    • 40349098656 scopus 로고    scopus 로고
    • Application of immunohistochemistry to gynecologic pathology
    • Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008;132:402-423.
    • (2008) Arch Pathol Lab Med , vol.132 , pp. 402-423
    • Mittal, K.1    Soslow, R.2    McCluggage, W.G.3
  • 46
    • 0035220843 scopus 로고    scopus 로고
    • Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia
    • Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001;115:32-38.
    • (2001) Am J Clin Pathol , vol.115 , pp. 32-38
    • Sun, H.1    Enomoto, T.2    Fujita, M.3
  • 47
    • 0037378452 scopus 로고    scopus 로고
    • Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia
    • Orbo A, Nilsen MN, Arnes MS, et al. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol. 2003;22:141-148.
    • (2003) Int J Gynecol Pathol , vol.22 , pp. 141-148
    • Orbo, A.1    Nilsen, M.N.2    Arnes, M.S.3
  • 48
    • 1542724875 scopus 로고    scopus 로고
    • Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression
    • Hecht JL, Pinkus JL, Pinkus GS. Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression. Appl Immunohistochem Mol Morphol. 2004;12:36-39.
    • (2004) Appl Immunohistochem Mol Morphol , vol.12 , pp. 36-39
    • Hecht, J.L.1    Pinkus, J.L.2    Pinkus, G.S.3
  • 49
    • 77955360642 scopus 로고    scopus 로고
    • Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer
    • Monte NM, Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res. 2010;70:6225-6232.
    • (2010) Cancer Res , vol.70 , pp. 6225-6232
    • Monte, N.M.1    Webster, K.A.2    Neuberg, D.3
  • 50
    • 84857155080 scopus 로고    scopus 로고
    • PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia
    • Allison KH, Upson K, Reed SD, et al. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. Int J Gynecol Pathol. 2012;31:151-159.
    • (2012) Int J Gynecol Pathol , vol.31 , pp. 151-159
    • Allison, K.H.1    Upson, K.2    Reed, S.D.3
  • 51
    • 84868142801 scopus 로고    scopus 로고
    • Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia
    • Quick CM, Laury AR, Monte NM, Mutter GL. Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol. 2012;138:678-684.
    • (2012) Am J Clin Pathol , vol.138 , pp. 678-684
    • Quick, C.M.1    Laury, A.R.2    Monte, N.M.3    Mutter, G.L.4
  • 52
    • 0031012928 scopus 로고    scopus 로고
    • P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
    • Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177-185.
    • (1997) Am J Pathol , vol.150 , pp. 177-185
    • Tashiro, H.1    Isacson, C.2    Levine, R.3
  • 53
    • 0031769404 scopus 로고    scopus 로고
    • P53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: Precursor of uterine papillary serous carcinoma
    • Zheng W, Khurana R, Farahmand S, et al. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998;22:1463-1473.
    • (1998) Am J Surg Pathol , vol.22 , pp. 1463-1473
    • Zheng, W.1    Khurana, R.2    Farahmand, S.3
  • 54
    • 42249113463 scopus 로고    scopus 로고
    • Endometrial glandular dysplasia with frequent p53 gene mutation: A genetic evidence supporting its precancer nature for endometrial serous carcinoma
    • Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14:2263-2269.
    • (2008) Clin Cancer Res , vol.14 , pp. 2263-2269
    • Jia, L.1    Liu, Y.2    Yi, X.3
  • 55
    • 0034651530 scopus 로고    scopus 로고
    • The frequency of p53 K-ras mutations and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways
    • Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-824.
    • (2000) Cancer , vol.88 , pp. 814-824
    • Lax, S.F.1    Kendall, B.2    Tashiro, H.3
  • 56
    • 0036134090 scopus 로고    scopus 로고
    • Distinction between endometrial and endocervical adenocarcinoma: An immunohistochemical study
    • Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21:4-10.
    • (2002) Int J Gynecol Pathol , vol.21 , pp. 4-10
    • Castrillon, D.H.1    Lee, K.R.2    Nucci, M.R.3
  • 57
    • 84856686339 scopus 로고    scopus 로고
    • P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin
    • Saad RS, Mashhour M, Noftech-Mozes S, et al. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin. Int J Gynecol Pathol. 2012;31:57-65.
    • (2012) Int J Gynecol Pathol , vol.31 , pp. 57-65
    • Saad, R.S.1    Mashhour, M.2    Noftech-Mozes, S.3
  • 58
    • 84857467696 scopus 로고    scopus 로고
    • Diagnostic implications of p16 expression in serous papillary endometrial cancer
    • Netzer IM, Kerner H, Litwin L, et al. Diagnostic implications of p16 expression in serous papillary endometrial cancer. Int J Gynecol Cancer. 2011;21:1441-1445.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 1441-1445
    • Netzer, I.M.1    Kerner, H.2    Litwin, L.3
  • 59
    • 84883463832 scopus 로고    scopus 로고
    • Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: Diagnostic pitfalls and clues to improve recognition of tumor origin
    • Bagby C, Ronnett BM, Yemelyanova A, et al. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin. Int J Gynecol Pathol. 2013;32:433-443.
    • (2013) Int J Gynecol Pathol , vol.32 , pp. 433-443
    • Bagby, C.1    Ronnett, B.M.2    Yemelyanova, A.3
  • 60
    • 0141680966 scopus 로고    scopus 로고
    • Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum
    • Hashi A, Yuminamochi T, Murata S, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003;22:374-377.
    • (2003) Int J Gynecol Pathol , vol.22 , pp. 374-377
    • Hashi, A.1    Yuminamochi, T.2    Murata, S.3
  • 61
    • 59149101397 scopus 로고    scopus 로고
    • A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary
    • Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
    • (2009) Am J Surg Pathol , vol.33 , pp. 14-21
    • Köbel, M.1    Kalloger, S.E.2    Carrick, J.3
  • 62
    • 1542270080 scopus 로고    scopus 로고
    • WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
    • Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115.
    • (2004) Histopathology , vol.44 , pp. 109-115
    • Al-Hussaini, M.1    Stockman, A.2    Foster, H.3    McCluggage, W.G.4
  • 63
    • 1642284785 scopus 로고    scopus 로고
    • Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium
    • Egan JA, Ionescu MC, Eapen E, et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol. 2004;23:119-122.
    • (2004) Int J Gynecol Pathol , vol.23 , pp. 119-122
    • Egan, J.A.1    Ionescu, M.C.2    Eapen, E.3
  • 64
    • 84926383409 scopus 로고    scopus 로고
    • Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: Interobserver reproducibility among ultrasound experts and gynecologists
    • Eriksson LS, Lindqvist PG, Flö ter Radestad A, et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound Obstet Gynecol. 2015;45:476-482.
    • (2015) Ultrasound Obstet Gynecol , vol.45 , pp. 476-482
    • Eriksson, L.S.1    Lindqvist, P.G.2    Flöter Radestad, A.3
  • 66
    • 0842304361 scopus 로고    scopus 로고
    • Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma
    • Scholten AN, Smit VT, Beerman H, et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer. 2004;100: 764-772.
    • (2004) Cancer , vol.100 , pp. 764-772
    • Scholten, A.N.1    Smit, V.T.2    Beerman, H.3
  • 67
    • 84893786639 scopus 로고    scopus 로고
    • Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer
    • Helpman L, Kupets R, Covens A, et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br J Cancer. 2014;110:609-615.
    • (2014) Br J Cancer , vol.110 , pp. 609-615
    • Helpman, L.1    Kupets, R.2    Covens, A.3
  • 68
    • 84901648475 scopus 로고    scopus 로고
    • Intra-operative frozen section results reliably predict final pathology in endometrial cancer
    • Stephan JM, Hansen J, Samuelson M, et al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol. 2014;133:499-505.
    • (2014) Gynecol Oncol , vol.133 , pp. 499-505
    • Stephan, J.M.1    Hansen, J.2    Samuelson, M.3
  • 69
    • 84886892919 scopus 로고    scopus 로고
    • HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: A prospective multicenter study (ENDOMET)
    • Antonsen SL, Høgdall E, Christensen IJ, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013;92:1313-1322.
    • (2013) Acta Obstet Gynecol Scand , vol.92 , pp. 1313-1322
    • Antonsen, S.L.1    Høgdall, E.2    Christensen, I.J.3
  • 70
    • 84866728682 scopus 로고    scopus 로고
    • Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma
    • Yildiz A, Yetimalar H, Kasap B, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012;164: 191-195.
    • (2012) Eur J Obstet Gynecol Reprod Biol. , vol.164 , pp. 191-195
    • Yildiz, A.1    Yetimalar, H.2    Kasap, B.3
  • 71
    • 84862886235 scopus 로고    scopus 로고
    • HE4 is an independent prognostic marker in endometrial cancer patients
    • Mutz-Dehbalaie I, Egle D, Fessler S, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012;126:186-191.
    • (2012) Gynecol Oncol , vol.126 , pp. 186-191
    • Mutz-Dehbalaie, I.1    Egle, D.2    Fessler, S.3
  • 72
    • 84883459439 scopus 로고    scopus 로고
    • Safety of ovarian preservation in young patients with early-stage endometrial cancer: A retrospective study and meta-analysis
    • Sun C, Chen G, Yang Z, et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril. 2013;100:782-787.
    • (2013) Fertil Steril , vol.100 , pp. 782-787
    • Sun, C.1    Chen, G.2    Yang, Z.3
  • 73
    • 73949107889 scopus 로고    scopus 로고
    • Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2
    • Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331-5336.
    • (2009) J Clin Oncol , vol.27 , pp. 5331-5336
    • Walker, J.L.1    Piedmonte, M.R.2    Spirtos, N.M.3
  • 74
    • 77955268275 scopus 로고    scopus 로고
    • Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: A randomised trial
    • Mourits MJ, Bijen CB, Arts HJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol. 2010;11:763-771.
    • (2010) Lancet Oncol , vol.11 , pp. 763-771
    • Mourits, M.J.1    Bijen, C.B.2    Arts, H.J.3
  • 75
    • 84862978252 scopus 로고    scopus 로고
    • Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: A systematic review and metaanalysis of randomized controlled trials
    • Zullo F, Falbo A, Palomba S. Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol. 2012;207:94-100.
    • (2012) Am J Obstet Gynecol , vol.207 , pp. 94-100
    • Zullo, F.1    Falbo, A.2    Palomba, S.3
  • 76
    • 84894027918 scopus 로고    scopus 로고
    • A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma
    • Pakish J, Soliman PT, Frumovitz M, et al. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol. 2014;132:366-371.
    • (2014) Gynecol Oncol , vol.132 , pp. 366-371
    • Pakish, J.1    Soliman, P.T.2    Frumovitz, M.3
  • 77
    • 15544373622 scopus 로고    scopus 로고
    • Analysis of morbidity in patients with endometrial cancer: Is there a commitment to offer laparoscopy
    • Tozzi R, Malur S, Koehler C, Schneider A. Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy Gynecol Oncol. 2005;97:4-9.
    • (2005) Gynecol Oncol , vol.97 , pp. 4-9
    • Tozzi, R.1    Malur, S.2    Koehler, C.3    Schneider, A.4
  • 78
    • 77952267504 scopus 로고    scopus 로고
    • Surgical and survival outcomes in older women with endometrial cancer treated by laparoscopy
    • Siesto G, Uccella S, Ghezzi F, et al. Surgical and survival outcomes in older women with endometrial cancer treated by laparoscopy. Menopause. 2010;17:539-544.
    • (2010) Menopause , vol.17 , pp. 539-544
    • Siesto, G.1    Uccella, S.2    Ghezzi, F.3
  • 79
    • 58149510327 scopus 로고    scopus 로고
    • Laparoscopic treatment for endometrial cancer: A meta-analysis of randomized controlled trials (RCTs)
    • Palomba S, Falbo A, Mocciaro R, et al. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol. 2009;112:415-421.
    • (2009) Gynecol Oncol , vol.112 , pp. 415-421
    • Palomba, S.1    Falbo, A.2    Mocciaro, R.3
  • 80
    • 67349124841 scopus 로고    scopus 로고
    • Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer
    • Palomba S, Falbo A, Russo T, Zullo F. Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer. Gynecol Oncol. 2009;114: 135-136.
    • (2009) Gynecol Oncol , vol.114 , pp. 135-136
    • Palomba, S.1    Falbo, A.2    Russo, T.3    Zullo, F.4
  • 81
    • 84863393302 scopus 로고    scopus 로고
    • Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
    • Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012;30:695-700.
    • (2012) J Clin Oncol , vol.30 , pp. 695-700
    • Walker, J.L.1    Piedmonte, M.R.2    Spirtos, N.M.3
  • 82
    • 84862862331 scopus 로고    scopus 로고
    • Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: A multi-site study performed at high volume cancer centers
    • Fader AN, Seamon LG, Escobar PF, et al. Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. Gynecol Oncol. 2012;126:180-185.
    • (2012) Gynecol Oncol , vol.126 , pp. 180-185
    • Fader, A.N.1    Seamon, L.G.2    Escobar, P.F.3
  • 83
    • 84905581356 scopus 로고    scopus 로고
    • Peritoneal cytology: A risk factor of recurrence for non-endometrioid endometrial cancer
    • Han KH, Park NH, Kim HS, et al. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer. Gynecol Oncol. 2014;134:293-296.
    • (2014) Gynecol Oncol , vol.134 , pp. 293-296
    • Han, K.H.1    Park, N.H.2    Kim, H.S.3
  • 84
    • 84871922686 scopus 로고    scopus 로고
    • Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer
    • Garg G, Gao F, Wright JD, et al. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013;128:77-82.
    • (2013) Gynecol Oncol , vol.128 , pp. 77-82
    • Garg, G.1    Gao, F.2    Wright, J.D.3
  • 85
    • 33745029084 scopus 로고    scopus 로고
    • Pelvic lymph node count is an important prognostic variable for FIGO stage i and II endometrial carcinoma with high-risk histology
    • Lutman CV, Havrilesky LJ, Cragun JM, et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006;102:92-97.
    • (2006) Gynecol Oncol , vol.102 , pp. 92-97
    • Lutman, C.V.1    Havrilesky, L.J.2    Cragun, J.M.3
  • 86
    • 41349095877 scopus 로고    scopus 로고
    • Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma
    • discussion 457.e5-e6
    • Abu-Rustum NR, Iasonos A, Zhou Q, et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma Am J Obstet Gynecol. 2008;198:457.e1-e5; discussion 457.e5-e6.
    • (2008) Am J Obstet Gynecol , vol.198 , Issue.457 , pp. e1-e5
    • Abu-Rustum, N.R.1    Iasonos, A.2    Zhou, Q.3
  • 87
    • 20544477431 scopus 로고    scopus 로고
    • Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer
    • Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23:3668-3675.
    • (2005) J Clin Oncol , vol.23 , pp. 3668-3675
    • Cragun, J.M.1    Havrilesky, L.J.2    Calingaert, B.3
  • 88
    • 0028942190 scopus 로고
    • Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling
    • Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995;56:29-33.
    • (1995) Gynecol Oncol , vol.56 , pp. 29-33
    • Kilgore, L.C.1    Partridge, E.E.2    Alvarez, R.D.3
  • 89
    • 0023232969 scopus 로고
    • Surgical pathologic spread patterns of endometrial cancer
    • A Gynecologic Oncology Group Study
    • Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60(suppl 8): 2035-2041.
    • (1987) Cancer , vol.60 , pp. 2035-2041
    • Creasman, W.T.1    Morrow, C.P.2    Bundy, B.N.3
  • 90
    • 70349745230 scopus 로고    scopus 로고
    • The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes
    • Abu-Rustum NR, Gomez JD, Alektiar KM, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol. 2009;115:236-238.
    • (2009) Gynecol Oncol , vol.115 , pp. 236-238
    • Abu-Rustum, N.R.1    Gomez, J.D.2    Alektiar, K.M.3
  • 91
    • 56449101720 scopus 로고    scopus 로고
    • Extra-peritoneal laparoscopic para-aortic lymphadenectomy-a prospective cohort study of 293 patients with endometrial cancer
    • Dowdy SC, Aletti G, Cliby WA, et al. Extra-peritoneal laparoscopic para-aortic lymphadenectomy-a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol. 2008;111:418-424.
    • (2008) Gynecol Oncol , vol.111 , pp. 418-424
    • Dowdy, S.C.1    Aletti, G.2    Cliby, W.A.3
  • 92
    • 40949141349 scopus 로고    scopus 로고
    • Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging
    • Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008;109:11-18.
    • (2008) Gynecol Oncol , vol.109 , pp. 11-18
    • Mariani, A.1    Dowdy, S.C.2    Cliby, W.A.3
  • 93
    • 79955483215 scopus 로고    scopus 로고
    • Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: A prospective multicentre study (SENTI-ENDO)
    • Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12:469-476.
    • (2011) Lancet Oncol , vol.12 , pp. 469-476
    • Ballester, M.1    Dubernard, G.2    Lécuru, F.3
  • 94
    • 84895828864 scopus 로고    scopus 로고
    • Sentinel lymph node mapping for endometrial cancer: A modern approach to surgical staging
    • Abu-Rustum NR. Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. J Natl Compr Canc Netw. 2014;12:288-297.
    • (2014) J Natl Compr Canc Netw , vol.12 , pp. 288-297
    • Abu-Rustum, N.R.1
  • 95
    • 57349198710 scopus 로고    scopus 로고
    • Systematic pelvic lymphadenectomy vs. No lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial
    • Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707-1716.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1707-1716
    • Benedetti Panici, P.1    Basile, S.2    Maneschi, F.3
  • 96
    • 58149191223 scopus 로고    scopus 로고
    • Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study
    • Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125-136.
    • (2009) Lancet , vol.373 , pp. 125-136
    • Kitchener, H.1    Swart, A.M.2    Qian, Q.3
  • 97
    • 84862771599 scopus 로고    scopus 로고
    • The role of lymphadenectomy in endometrial cancer: Was the ASTEC trial doomed by design and are we destined to repeat that mistake
    • Naumann RW. The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake Gynecol Oncol. 2012;126:5-11.
    • (2012) Gynecol Oncol , vol.126 , pp. 5-11
    • Naumann, R.W.1
  • 98
    • 40549135709 scopus 로고    scopus 로고
    • Survival impact of lymph node dissection in endometrial adenocarcinoma: A surveillance, epidemiology, and end results analysis
    • Smith DC, Macdonald OK, Lee CM, Gaffney DK. Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer. 2008;18:255-261.
    • (2008) Int J Gynecol Cancer , vol.18 , pp. 255-261
    • Smith, D.C.1    MacDonald, O.K.2    Lee, C.M.3    Gaffney, D.K.4
  • 99
    • 0032422316 scopus 로고    scopus 로고
    • Lymph node sampling and survival in endometrial cancer
    • Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998;71: 340-343.
    • (1998) Gynecol Oncol , vol.71 , pp. 340-343
    • Trimble, E.L.1    Kosary, C.2    Park, R.C.3
  • 100
    • 77950188128 scopus 로고    scopus 로고
    • Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): A retrospective cohort analysis
    • Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165-1172.
    • (2010) Lancet , vol.375 , pp. 1165-1172
    • Todo, Y.1    Kato, H.2    Kaneuchi, M.3
  • 101
    • 33750063659 scopus 로고    scopus 로고
    • Therapeutic role of lymph node resection in endometrioid corpus cancer: A study of 12,333 patients
    • Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107:1823-1830.
    • (2006) Cancer , vol.107 , pp. 1823-1830
    • Chan, J.K.1    Cheung, M.K.2    Huh, W.K.3
  • 102
    • 84860475076 scopus 로고    scopus 로고
    • Systematic lymphadenectomy for survival in patients with endometrial cancer: A meta-analysis
    • Kim HS, Suh DH, Kim MK, et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol. 2012;42:405-412.
    • (2012) Jpn J Clin Oncol , vol.42 , pp. 405-412
    • Kim, H.S.1    Suh, D.H.2    Kim, M.K.3
  • 103
    • 84899654500 scopus 로고    scopus 로고
    • Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: A SEER analysis
    • Vargas R, Rauh-Hain JA, Clemmer J, et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014;133:216-220.
    • (2014) Gynecol Oncol , vol.133 , pp. 216-220
    • Vargas, R.1    Rauh-Hain, J.A.2    Clemmer, J.3
  • 104
    • 84885173275 scopus 로고    scopus 로고
    • Surgery for endometrial cancers with suspected cervical involvement: Is radical hysterectomy needed (a GOTIC study)
    • Takano M, Ochi H, Takei Y, et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study) Br J Cancer. 2013;109:1760-1765.
    • (2013) Br J Cancer , vol.109 , pp. 1760-1765
    • Takano, M.1    Ochi, H.2    Takei, Y.3
  • 105
    • 78049335265 scopus 로고    scopus 로고
    • Evaluation of parametrial spread in endometrial carcinoma
    • Watanabe Y, Satou T, Nakai H, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol. 2010;116: 1027-1034.
    • (2010) Obstet Gynecol , vol.116 , pp. 1027-1034
    • Watanabe, Y.1    Satou, T.2    Nakai, H.3
  • 106
    • 40749152740 scopus 로고    scopus 로고
    • Classification of radical hysterectomy
    • Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9:297-303.
    • (2008) Lancet Oncol , vol.9 , pp. 297-303
    • Querleu, D.1    Morrow, C.P.2
  • 107
    • 80051550748 scopus 로고    scopus 로고
    • Surgical cytoreduction in stage IV endometrioid endometrial carcinoma
    • Shih KK, Yun E, Gardner GJ, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol. 2011;122:608-611.
    • (2011) Gynecol Oncol , vol.122 , pp. 608-611
    • Shih, K.K.1    Yun, E.2    Gardner, G.J.3
  • 108
    • 79956078774 scopus 로고    scopus 로고
    • The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: A collaborative study
    • Vandenput I, Trovik J, Vergote I, et al. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer. 2011;21:332-336.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 332-336
    • Vandenput, I.1    Trovik, J.2    Vergote, I.3
  • 109
    • 84925855902 scopus 로고    scopus 로고
    • Clinical outcomes of uterine carcinosarcoma: Results of 94 patients
    • Gokce ZK, Turan T, Karalok A, et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer. 2015;25:279-287.
    • (2015) Int J Gynecol Cancer , vol.25 , pp. 279-287
    • Gokce, Z.K.1    Turan, T.2    Karalok, A.3
  • 110
    • 23444461364 scopus 로고    scopus 로고
    • Endometrial cancer
    • Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491-505.
    • (2005) Lancet , vol.366 , pp. 491-505
    • Amant, F.1    Moerman, P.2    Neven, P.3
  • 111
    • 13844256730 scopus 로고    scopus 로고
    • Lymphvascular space involvement: An independent prognostic factor in endometrial cancer
    • Briët JM, Hollema H, Reesink N, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96:799-804.
    • (2005) Gynecol Oncol , vol.96 , pp. 799-804
    • Briët, J.M.1    Hollema, H.2    Reesink, N.3
  • 112
    • 0036921816 scopus 로고    scopus 로고
    • Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer
    • Cohn DE, Horowitz NS, Mutch DG, et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer Gynecol Oncol. 2002;87:243-246.
    • (2002) Gynecol Oncol , vol.87 , pp. 243-246
    • Cohn, D.E.1    Horowitz, N.S.2    Mutch, D.G.3
  • 113
    • 67650069978 scopus 로고    scopus 로고
    • Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer
    • Gadducci A, Cavazzana A, Cosio S, et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res. 2009;29:1715-1720.
    • (2009) Anticancer Res , vol.29 , pp. 1715-1720
    • Gadducci, A.1    Cavazzana, A.2    Cosio, S.3
  • 114
    • 34248566806 scopus 로고    scopus 로고
    • Lymphvascular space involvement compromises the survival of patients with stage i endometrial cancer: Results of a multicenter study
    • Gemer O, Arie AB, Levy T, et al. Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. Eur J Surg Oncol. 2007;33:644-647.
    • (2007) Eur J Surg Oncol , vol.33 , pp. 644-647
    • Gemer, O.1    Arie, A.B.2    Levy, T.3
  • 115
    • 83055184368 scopus 로고    scopus 로고
    • Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer
    • Guntupalli SR, Zighelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012;124:31-35.
    • (2012) Gynecol Oncol , vol.124 , pp. 31-35
    • Guntupalli, S.R.1    Zighelboim, I.2    Kizer, N.T.3
  • 116
    • 58149186453 scopus 로고    scopus 로고
    • Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and meta-analysis
    • Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137-146.
    • (2009) Lancet , vol.373 , pp. 137-146
    • Blake, P.1    Swart, A.M.2    Orton, J.3
  • 117
    • 18144432776 scopus 로고    scopus 로고
    • Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial
    • PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma
    • Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355: 1404-1411.
    • (2000) Lancet , vol.355 , pp. 1404-1411
    • Creutzberg, C.L.1    Van Putten, W.L.2    Koper, P.C.3
  • 118
    • 1342321840 scopus 로고    scopus 로고
    • A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study
    • Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
    • (2004) Gynecol Oncol , vol.92 , pp. 744-751
    • Keys, H.M.1    Roberts, J.A.2    Brunetto, V.L.3
  • 119
    • 84869016236 scopus 로고    scopus 로고
    • Adjuvant radiotherapy for stage i endometrial cancer: An updated Cochrane systematic review and meta-analysis
    • Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:1625-1634.
    • (2012) J Natl Cancer Inst , vol.104 , pp. 1625-1634
    • Kong, A.1    Johnson, N.2    Kitchener, H.C.3    Lawrie, T.A.4
  • 120
    • 0029738560 scopus 로고    scopus 로고
    • Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
    • Soong R, Knowles S, Williams KE, et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer. 1996;74:562-567.
    • (1996) Br J Cancer , vol.74 , pp. 562-567
    • Soong, R.1    Knowles, S.2    Williams, K.E.3
  • 121
    • 0032896335 scopus 로고    scopus 로고
    • Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study
    • Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol. 1999;17:1382-1390.
    • (1999) J Clin Oncol , vol.17 , pp. 1382-1390
    • Salvesen, H.B.1    Iversen, O.E.2    Akslen, L.A.3
  • 122
    • 84901673573 scopus 로고    scopus 로고
    • Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer
    • AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133:485-493.
    • (2014) Gynecol Oncol , vol.133 , pp. 485-493
    • Alhilli, M.M.1    Mariani, A.2    Bakkum-Gamez, J.N.3
  • 123
    • 84881657484 scopus 로고    scopus 로고
    • L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation
    • Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013;105:1142-1150.
    • (2013) J Natl Cancer Inst , vol.105 , pp. 1142-1150
    • Zeimet, A.G.1    Reimer, D.2    Huszar, M.3
  • 124
    • 84907430202 scopus 로고    scopus 로고
    • L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results
    • Bosse T, Nout RA, Stelloo E, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer. 2014;50:2602-2610.
    • (2014) Eur J Cancer , vol.50 , pp. 2602-2610
    • Bosse, T.1    Nout, R.A.2    Stelloo, E.3
  • 125
    • 69449098469 scopus 로고    scopus 로고
    • Intravaginal brachytherapy in FIGO stage i low-risk endometrial cancer: A controlled randomized study
    • Sorbe B, Nordström B, Maënpaä J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009;19:873-878.
    • (2009) Int J Gynecol Cancer , vol.19 , pp. 873-878
    • Sorbe, B.1    Nordström, B.2    Maënpaä, J.3
  • 126
    • 77649130174 scopus 로고    scopus 로고
    • Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial
    • Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816-823.
    • (2010) Lancet , vol.375 , pp. 816-823
    • Nout, R.A.1    Smit, V.T.2    Putter, H.3
  • 127
    • 84856376656 scopus 로고    scopus 로고
    • External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma-a prospective randomized study
    • Sorbe B, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma-a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82:1249-1255.
    • (2012) Int J Radiat Oncol Biol Phys , vol.82 , pp. 1249-1255
    • Sorbe, B.1    Horvath, G.2    Andersson, H.3
  • 128
    • 84938740095 scopus 로고    scopus 로고
    • Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer-A pooled analysis of PORTEC 1 and 2 trials
    • Bosse T, Peters EE, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer-A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51:1742-1750.
    • (2015) Eur J Cancer , vol.51 , pp. 1742-1750
    • Bosse, T.1    Peters, E.E.2    Creutzberg, C.L.3
  • 129
    • 84901633332 scopus 로고    scopus 로고
    • A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer Impact of lymphovascular space invasion
    • Bendifallah S, Canlorbe G, Raimond E, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer Impact of lymphovascular space invasion. Br J Cancer. 2014;110:2640-2646.
    • (2014) Br J Cancer , vol.110 , pp. 2640-2646
    • Bendifallah, S.1    Canlorbe, G.2    Raimond, E.3
  • 130
    • 0344626922 scopus 로고    scopus 로고
    • Survival after relapse in patients with endometrial cancer: Results from a randomized trial
    • Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201-209.
    • (2003) Gynecol Oncol , vol.89 , pp. 201-209
    • Creutzberg, C.L.1    Van Putten, W.L.2    Koper, P.C.3
  • 131
    • 84923088717 scopus 로고    scopus 로고
    • A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial
    • McMeekin DS, Filiaci VL, Aghajanian C, et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial. Gynecol Oncol. 2014;134:438 (abstract LBA 431).
    • (2014) Gynecol Oncol , vol.134 , pp. 438
    • McMeekin, D.S.1    Filiaci, V.L.2    Aghajanian, C.3
  • 132
    • 33845229580 scopus 로고    scopus 로고
    • Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
    • Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S105-S143.
    • (2006) Int J Gynaecol Obstet , vol.95 , pp. S105-143
    • Creasman, W.T.1    Odicino, F.2    Maisonneuve, P.3
  • 133
    • 0024997768 scopus 로고
    • Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium
    • Greven KM, Randall M, Fanning J, et al. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 1990;19:529-534.
    • (1990) Int J Radiat Oncol Biol Phys , vol.19 , pp. 529-534
    • Greven, K.M.1    Randall, M.2    Fanning, J.3
  • 134
    • 0037404778 scopus 로고    scopus 로고
    • Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy
    • Straughn JM, Huh WK, Orr JW Jr, et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol. 2003;89:295-300.
    • (2003) Gynecol Oncol , vol.89 , pp. 295-300
    • Straughn, J.M.1    Huh, W.K.2    Orr, Jr.J.W.3
  • 135
    • 2142640269 scopus 로고    scopus 로고
    • Outcome of high-risk stage IC, grade 3, compared with stage i endometrial carcinoma patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial
    • Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22:1234-1241.
    • (2004) J Clin Oncol , vol.22 , pp. 1234-1241
    • Creutzberg, C.L.1    Van Putten, W.L.2    Wárlám-Rodenhuis, C.C.3
  • 136
    • 84936082191 scopus 로고    scopus 로고
    • Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
    • Sagae S, Susumu N, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer. 2014;24 (9 suppl 3):S83-S89.
    • (2014) Int J Gynecol Cancer , vol.24 , Issue.9 , pp. S83-S89
    • Sagae, S.1    Susumu, N.2    Viswanathan, A.N.3
  • 137
    • 0025021388 scopus 로고
    • Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage i and occult stage II: A Gynecologic Oncology Group Study
    • Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990;36:166-171.
    • (1990) Gynecol Oncol , vol.36 , pp. 166-171
    • Morrow, C.P.1    Bundy, B.N.2    Homesley, H.D.3
  • 138
    • 37349026899 scopus 로고    scopus 로고
    • Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study
    • Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226-233.
    • (2008) Gynecol Oncol , vol.108 , pp. 226-233
    • Susumu, N.1    Sagae, S.2    Udagawa, Y.3
  • 139
    • 33746911931 scopus 로고    scopus 로고
    • Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial
    • Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95:266-271.
    • (2006) Br J Cancer , vol.95 , pp. 266-271
    • Maggi, R.1    Lissoni, A.2    Spina, F.3
  • 140
    • 77955918294 scopus 로고    scopus 로고
    • Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies
    • Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422-2431.
    • (2010) Eur J Cancer , vol.46 , pp. 2422-2431
    • Hogberg, T.1    Signorelli, M.2    De Oliveira, C.F.3
  • 141
    • 33748549388 scopus 로고    scopus 로고
    • Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer
    • Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006;103:155-159.
    • (2006) Gynecol Oncol , vol.103 , pp. 155-159
    • Greven, K.1    Winter, K.2    Underhill, K.3
  • 142
    • 80052511021 scopus 로고    scopus 로고
    • Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes
    • Cooke EW, Pappas L, Gaffney DK. Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes Cancer. 2011;117:4231-4237.
    • (2011) Cancer , vol.117 , pp. 4231-4237
    • Cooke, E.W.1    Pappas, L.2    Gaffney, D.K.3
  • 143
    • 84861485091 scopus 로고    scopus 로고
    • Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies Revised staging, endometrial cancer, histology
    • Page BR, Pappas L, Cooke EW, Gaffney DK. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies Revised staging, endometrial cancer, histology. Int J Gynecol Cancer. 2012;22:593-598.
    • (2012) Int J Gynecol Cancer , vol.22 , pp. 593-598
    • Page, B.R.1    Pappas, L.2    Cooke, E.W.3    Gaffney, D.K.4
  • 144
    • 64049094855 scopus 로고    scopus 로고
    • Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium
    • Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103-104.
    • (2009) Int J Gynaecol Obstet , vol.105 , pp. 103-104
    • Pecorelli, S.1
  • 145
    • 0026060964 scopus 로고
    • Relationship between surgical-pathological risk factors and outcome in clinical stage i and II carcinoma of the endometrium: A Gynecologic Oncology Group study
    • Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55-65.
    • (1991) Gynecol Oncol , vol.40 , pp. 55-65
    • Morrow, C.P.1    Bundy, B.N.2    Kurman, R.J.3
  • 146
    • 62549128168 scopus 로고    scopus 로고
    • Optimizing the management of stage II endometrial cancer: The role of radical hysterectomy and radiation
    • Wright JD, Fiorelli J, Kansler AL, et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009;200:419.e1-e7.
    • (2009) Am J Obstet Gynecol , vol.200 , Issue.419 , pp. e1-e7
    • Wright, J.D.1    Fiorelli, J.2    Kansler, A.L.3
  • 147
    • 84898812959 scopus 로고    scopus 로고
    • The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline
    • Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014;4: 137-144.
    • (2014) Pract Radiat Oncol , vol.4 , pp. 137-144
    • Klopp, A.1    Smith, B.D.2    Alektiar, K.3
  • 148
    • 37049029629 scopus 로고    scopus 로고
    • Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: A SEER registry analysis
    • Rossi PJ, Jani AB, Horowitz IR, Johnstone PA. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. Int J Radiat Oncol Biol Phys. 2008;70:134-138.
    • (2008) Int J Radiat Oncol Biol Phys , vol.70 , pp. 134-138
    • Rossi, P.J.1    Jani, A.B.2    Horowitz, I.R.3    Johnstone, P.A.4
  • 149
    • 0025334384 scopus 로고
    • Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma
    • Randall ME, Wilder J, Greven K, Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1990;19:49-54.
    • (1990) Int J Radiat Oncol Biol Phys , vol.19 , pp. 49-54
    • Randall, M.E.1    Wilder, J.2    Greven, K.3    Raben, M.4
  • 150
    • 13844301241 scopus 로고    scopus 로고
    • Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer
    • Greven K, Winter K, Underhill K, et al. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004;59:168-173.
    • (2004) Int J Radiat Oncol Biol Phys , vol.59 , pp. 168-173
    • Greven, K.1    Winter, K.2    Underhill, K.3
  • 151
    • 79957840766 scopus 로고    scopus 로고
    • Postoperative radiotherapy in stage I/II endometrial cancer: Retrospective analysis of 883 patients treated at the University of Florence
    • Scotti V, Borghesi S, Meattini I, et al. Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer. 2010;20:1540-1548.
    • (2010) Int J Gynecol Cancer , vol.20 , pp. 1540-1548
    • Scotti, V.1    Borghesi, S.2    Meattini, I.3
  • 152
    • 51749103754 scopus 로고    scopus 로고
    • Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma
    • Jobsen JJ, Lybeert ML, van der Steen-Banasik EM, et al. Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma. Int J Gynecol Cancer. 2008;18:1071-1078.
    • (2008) Int J Gynecol Cancer , vol.18 , pp. 1071-1078
    • Jobsen, J.J.1    Lybeert, M.L.2    Van Der Steen-Banasik, E.M.3
  • 153
    • 77956628579 scopus 로고    scopus 로고
    • Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage i and II endometrial carcinoma
    • Crosby MA, Tward JD, Szabo A, et al. Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma Am J Clin Oncol. 2010;33:364-369.
    • (2010) Am J Clin Oncol , vol.33 , pp. 364-369
    • Crosby, M.A.1    Tward, J.D.2    Szabo, A.3
  • 154
    • 84871918512 scopus 로고    scopus 로고
    • A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
    • Secord AA, Geller MA, Broadwater G, et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol. 2013;128:65-70.
    • (2013) Gynecol Oncol , vol.128 , pp. 65-70
    • Secord, A.A.1    Geller, M.A.2    Broadwater, G.3
  • 155
    • 69149098489 scopus 로고    scopus 로고
    • Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation
    • Klopp AH, Jhingran A, Ramondetta L, et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009;115:6-11.
    • (2009) Gynecol Oncol , vol.115 , pp. 6-11
    • Klopp, A.H.1    Jhingran, A.2    Ramondetta, L.3
  • 156
    • 33644836069 scopus 로고    scopus 로고
    • Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study
    • Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36-44.
    • (2006) J Clin Oncol , vol.24 , pp. 36-36
    • Randall, M.E.1    Filiaci, V.L.2    Muss, H.3
  • 157
    • 84865692661 scopus 로고    scopus 로고
    • Combined chemotherapy and radiation improves survival for node-positive endometrial cancer
    • Lee LJ, Viswanathan AN. Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Gynecol Oncol. 2012;127:32-37.
    • (2012) Gynecol Oncol , vol.127 , pp. 32-37
    • Lee, L.J.1    Viswanathan, A.N.2
  • 158
    • 0035425310 scopus 로고    scopus 로고
    • Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy
    • Mundt AJ, McBride R, Rotmensch J, et al. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:1145-1153.
    • (2001) Int J Radiat Oncol Biol Phys , vol.50 , pp. 1145-1153
    • Mundt, A.J.1    McBride, R.2    Rotmensch, J.3
  • 159
    • 81155148254 scopus 로고    scopus 로고
    • The importance of chemotherapy and radiation in uterine papillary serous carcinoma
    • Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011;123:542-547.
    • (2011) Gynecol Oncol , vol.123 , pp. 542-547
    • Viswanathan, A.N.1    MacKlin, E.A.2    Berkowitz, R.3    Matulonis, U.4
  • 160
    • 84936108299 scopus 로고    scopus 로고
    • Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix
    • Hasegawa K, Nagao S, Yasuda M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer. 2014;24(9 suppl 3):S90Y-95.
    • (2014) Int J Gynecol Cancer , vol.24 , Issue.9 , pp. S90-S95
    • Hasegawa, K.1    Nagao, S.2    Yasuda, M.3
  • 161
    • 84871394939 scopus 로고    scopus 로고
    • The role of vaginal brachytherapy in the treatment of surgical stage i papillary serous or clear cell endometrial cancer
    • Barney BM, Petersen IA, Mariani A, et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys. 2013;85:109-115.
    • (2013) Int J Radiat Oncol Biol Phys , vol.85 , pp. 109-115
    • Barney, B.M.1    Petersen, I.A.2    Mariani, A.3
  • 162
    • 84923136396 scopus 로고    scopus 로고
    • Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma
    • Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 suppl 3):S55-S60.
    • (2014) Int J Gynecol Cancer , vol.24 , Issue.9 , pp. S55-S60
    • Berton-Rigaud, D.1    Devouassoux-Shisheboran, M.2    Ledermann, J.A.3
  • 163
    • 27144505774 scopus 로고    scopus 로고
    • The rationale for comprehensive surgical staging in endometrial carcinosarcoma
    • author reply 522-523
    • Amant F. The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecol Oncol. 2005;99: 521-522; author reply 522-523.
    • (2005) Gynecol Oncol , vol.99 , pp. 521-522
    • Amant, F.1
  • 164
    • 41849100978 scopus 로고    scopus 로고
    • Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages i and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)
    • Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808-818.
    • (2008) Eur J Cancer , vol.44 , pp. 808-818
    • Reed, N.S.1    Mangioni, C.2    Malmstrom, H.3
  • 165
    • 54849407769 scopus 로고    scopus 로고
    • The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma
    • Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199:536.e1-e8.
    • (2008) Am J Obstet Gynecol , vol.199 , Issue.536 , pp. e1-e8
    • Wright, J.D.1    Seshan, V.E.2    Shah, M.3
  • 166
    • 49149090815 scopus 로고    scopus 로고
    • The impact of adjuvant radiation therapy on survival inwomen with uterine carcinosarcoma
    • Clayton Smith D, Kenneth Macdonald O, Gaffney DK. The impact of adjuvant radiation therapy on survival inwomen with uterine carcinosarcoma. Radiother Oncol. 2008;88:227-232.
    • (2008) Radiother Oncol , vol.88 , pp. 227-232
    • Clayton Smith, D.1    Kenneth MacDonald, O.2    Gaffney, D.K.3
  • 167
    • 52049118515 scopus 로고    scopus 로고
    • Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: A SEER analysis
    • Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111:82-88.
    • (2008) Gynecol Oncol , vol.111 , pp. 82-88
    • Nemani, D.1    Mitra, N.2    Guo, M.3    Lin, L.4
  • 168
    • 35348917431 scopus 로고    scopus 로고
    • A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. Cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus
    • Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177-185.
    • (2007) Gynecol Oncol , vol.107 , pp. 177-185
    • Wolfson, A.H.1    Brady, M.F.2    Rocereto, T.3
  • 169
    • 77953285328 scopus 로고    scopus 로고
    • Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis
    • Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118:14-18.
    • (2010) Gynecol Oncol , vol.118 , pp. 14-18
    • Barlin, J.N.1    Puri, I.2    Bristow, R.E.3
  • 170
    • 10044243565 scopus 로고    scopus 로고
    • Prognosis of papillary serous, clear cell, and grade 3 stage i carcinoma of the endometrium
    • Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95:593-596.
    • (2004) Gynecol Oncol , vol.95 , pp. 593-596
    • Creasman, W.T.1    Kohler, M.F.2    Odicino, F.3
  • 171
    • 0038164996 scopus 로고    scopus 로고
    • Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy
    • Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003;56:1366-1372.
    • (2003) Int J Radiat Oncol Biol Phys , vol.56 , pp. 1366-1372
    • Jhingran, A.1    Burke, T.W.2    Eifel, P.J.3
  • 172
    • 84922598070 scopus 로고    scopus 로고
    • Definitive salvage for vaginal recurrence of endometrial cancer: The impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification
    • Vargo JA, Kim H, Houser CJ, et al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification. Radiother Oncol. 2014;113:126-131.
    • (2014) Radiother Oncol , vol.113 , pp. 126-131
    • Vargo, J.A.1    Kim, H.2    Houser, C.J.3
  • 173
    • 83055184395 scopus 로고    scopus 로고
    • Primary radiation therapy for medically inoperable patients with clinical stage i and II endometrial carcinoma
    • Podzielinski I, Randall ME, Breheny PJ, et al. Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. Gynecol Oncol. 2012;124:36-41.
    • (2012) Gynecol Oncol , vol.124 , pp. 36-41
    • Podzielinski, I.1    Randall, M.E.2    Breheny, P.J.3
  • 174
    • 0029867523 scopus 로고    scopus 로고
    • Radiation therapy as exclusive treatment for medically inoperable patients with stage i and II endometrioid carcinoma with endometrium
    • Fishman DA, Roberts KB, Chambers JT, et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol. 1996;61:189-196.
    • (1996) Gynecol Oncol , vol.61 , pp. 189-196
    • Fishman, D.A.1    Roberts, K.B.2    Chambers, J.T.3
  • 175
    • 84908280258 scopus 로고    scopus 로고
    • Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma
    • Gill BS, Kim H, Houser C, et al. Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma. Brachytherapy. 2014;13:542-547.
    • (2014) Brachytherapy , vol.13 , pp. 542-547
    • Gill, B.S.1    Kim, H.2    Houser, C.3
  • 176
    • 0033003177 scopus 로고    scopus 로고
    • Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group
    • Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17: 1736-1744.
    • (1999) J Clin Oncol , vol.17 , pp. 1736-1744
    • Thigpen, J.T.1    Brady, M.F.2    Alvarez, R.D.3
  • 177
    • 34548700355 scopus 로고    scopus 로고
    • Hormone therapy in advanced and recurrent endometrial cancer: A systematic review
    • Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964-978.
    • (2007) Int J Gynecol Cancer , vol.17 , pp. 964-978
    • Decruze, S.B.1    Green, J.A.2
  • 178
    • 84922481485 scopus 로고    scopus 로고
    • Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions
    • Tangen IL, Werner HM, Berg A, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014;50:3003-3010.
    • (2014) Eur J Cancer , vol.50 , pp. 3003-3010
    • Tangen, I.L.1    Werner, H.M.2    Berg, A.3
  • 179
    • 0030032844 scopus 로고    scopus 로고
    • High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study
    • Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357-361.
    • (1996) J Clin Oncol , vol.14 , pp. 357-361
    • Lentz, S.S.1    Brady, M.F.2    Major, F.J.3
  • 180
    • 0035863402 scopus 로고    scopus 로고
    • Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
    • Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19:364-367.
    • (2001) J Clin Oncol , vol.19 , pp. 364-367
    • Thigpen, T.1    Brady, M.F.2    Homesley, H.D.3
  • 181
    • 20844434805 scopus 로고    scopus 로고
    • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group
    • Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14:650-658.
    • (2004) Int J Gynecol Cancer , vol.14 , pp. 650-658
    • Ma, B.B.1    Oza, A.2    Eisenhauer, E.3
  • 182
    • 0033838806 scopus 로고    scopus 로고
    • A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    • Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78:212-216.
    • (2000) Gynecol Oncol , vol.78 , pp. 212-216
    • Rose, P.G.1    Brunetto, V.L.2    VanLe, L.3
  • 183
    • 0742324890 scopus 로고    scopus 로고
    • Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study
    • Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:4-9.
    • (2004) Gynecol Oncol , vol.92 , pp. 4-9
    • Whitney, C.W.1    Brunetto, V.L.2    Zaino, R.J.3
  • 184
    • 0742307280 scopus 로고    scopus 로고
    • Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study
    • Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10-14.
    • (2004) Gynecol Oncol , vol.92 , pp. 10-14
    • Fiorica, J.V.1    Brunetto, V.L.2    Hanjani, P.3
  • 185
    • 0037352608 scopus 로고    scopus 로고
    • Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
    • van Wijk FH, Aapro MS, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol. 2003;14:441-448.
    • (2003) Ann Oncol , vol.14 , pp. 441-448
    • Van Wijk, F.H.1    Aapro, M.S.2    Bolis, G.3
  • 186
    • 5444224343 scopus 로고    scopus 로고
    • Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynecologic oncology group study
    • Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902-3908.
    • (2004) J Clin Oncol , vol.22 , pp. 3902-3908
    • Thigpen, J.T.1    Brady, M.F.2    Homesley, H.D.3
  • 187
    • 2942657617 scopus 로고    scopus 로고
    • Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study
    • Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
    • (2004) J Clin Oncol , vol.22 , pp. 2159-2166
    • Fleming, G.F.1    Brunetto, V.L.2    Cella, D.3
  • 188
    • 84870532408 scopus 로고    scopus 로고
    • Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
    • Miller D, Filiaci V, Fleming G, et al. Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:771.
    • (2012) Gynecol Oncol , vol.125 , pp. 771
    • Miller, D.1    Filiaci, V.2    Fleming, G.3
  • 189
    • 84880434475 scopus 로고    scopus 로고
    • Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009
    • Makker V, Hensley ML, Zhou Q, et al. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer. 2013;23:929-934.
    • (2013) Int J Gynecol Cancer , vol.23 , pp. 929-934
    • Makker, V.1    Hensley, M.L.2    Zhou, Q.3
  • 190
    • 84863686900 scopus 로고    scopus 로고
    • Gemcitabine for advanced endometrial cancer: A retrospective study of the Memorial Sloan-Kettering Cancer Center experience
    • Grisham RN, Adaniel C, Hyman DM, et al. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial Sloan-Kettering Cancer Center experience. Int J Gynecol Cancer. 2012;22:807-811.
    • (2012) Int J Gynecol Cancer , vol.22 , pp. 807-811
    • Grisham, R.N.1    Adaniel, C.2    Hyman, D.M.3
  • 191
    • 84888285940 scopus 로고    scopus 로고
    • Applicability of the concept of platinum sensitivity" to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study
    • Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131:567-573.
    • (2013) Gynecol Oncol , vol.131 , pp. 567-573
    • Nagao, S.1    Nishio, S.2    Michimae, H.3
  • 192
    • 78649559263 scopus 로고    scopus 로고
    • Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer: A Gynecologic Oncology Group ancillary data analysis
    • Moore KN, Tian C, McMeekin DS, et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer: a Gynecologic Oncology Group ancillary data analysis. Cancer. 2010;116: 5407-5414.
    • (2010) Cancer , vol.116 , pp. 5407-5414
    • Moore, K.N.1    Tian, C.2    McMeekin, D.S.3
  • 193
    • 84871121234 scopus 로고    scopus 로고
    • Molecular pathology of endometrial carcinoma
    • Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111-123.
    • (2013) Histopathology , vol.62 , pp. 111-123
    • Matias-Guiu, X.1    Prat, J.2
  • 194
    • 63849308483 scopus 로고    scopus 로고
    • Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
    • Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA. 2009;106:4834-4839.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 4834-4839
    • Salvesen, H.B.1    Carter, S.L.2    Mannelqvist, M.3
  • 195
    • 84886394046 scopus 로고    scopus 로고
    • New strategies in endometrial cancer: Targeting the PI3K/mTOR pathway-the devil is in the details
    • Myers AP. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway-the devil is in the details. Clin Cancer Res. 2013;19:5264-5274.
    • (2013) Clin Cancer Res , vol.19 , pp. 5264-5274
    • Myers, A.P.1
  • 196
    • 84873059633 scopus 로고    scopus 로고
    • Endometrial carcinoma: Molecular alterations involved in tumor development and progression
    • Yeramian A, Moreno-Bueno G, Dolcet X, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32:403-413.
    • (2013) Oncogene , vol.32 , pp. 403-413
    • Yeramian, A.1    Moreno-Bueno, G.2    Dolcet, X.3
  • 197
    • 47249122523 scopus 로고    scopus 로고
    • Drug-sensitive FGFR2 mutations in endometrial carcinoma
    • Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA. 2008;105:8713-8717.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 8713-8717
    • Dutt, A.1    Salvesen, H.B.2    Chen, T.H.3
  • 198
    • 37549006796 scopus 로고    scopus 로고
    • Clinical and biological significance of vascular endothelial growth factor in endometrial cancer
    • Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13:7487-7495.
    • (2007) Clin Cancer Res , vol.13 , pp. 7487-7495
    • Kamat, A.A.1    Merritt, W.M.2    Coffey, D.3
  • 199
    • 84864330983 scopus 로고    scopus 로고
    • Markers for individualised therapy in endometrial carcinoma
    • Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13:e353-e361.
    • (2012) Lancet Oncol , vol.13 , pp. e353-e361
    • Salvesen, H.B.1    Haldorsen, I.S.2    Trovik, J.3
  • 200
    • 79955577284 scopus 로고    scopus 로고
    • Emerging therapeutic targets in endometrial cancer
    • Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261-271.
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 261-271
    • Dedes, K.J.1    Wetterskog, D.2    Ashworth, A.3
  • 201
    • 79957949444 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
    • Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29:2259-2265.
    • (2011) J Clin Oncol , vol.29 , pp. 2259-2265
    • Aghajanian, C.1    Sill, M.W.2    Darcy, K.M.3
  • 202
    • 84875435116 scopus 로고    scopus 로고
    • Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial
    • Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108:1021-1026.
    • (2013) Br J Cancer , vol.108 , pp. 1021-1026
    • Colombo, N.1    McMeekin, D.S.2    Schwartz, P.E.3
  • 203
    • 84913606847 scopus 로고    scopus 로고
    • Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
    • Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135:184-189.
    • (2014) Gynecol Oncol , vol.135 , pp. 184-189
    • Tsoref, D.1    Welch, S.2    Lau, S.3
  • 204
    • 84961812656 scopus 로고    scopus 로고
    • A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG86P
    • Aghajanian C, Filiaci VL, Dizon DS, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG86P. J Clin Oncol. 2015;33(suppl): abstract 5500.
    • (2015) J Clin Oncol , vol.33
    • Aghajanian, C.1    Filiaci, V.L.2    Dizon, D.S.3
  • 205
    • 84954370544 scopus 로고    scopus 로고
    • Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage IIIYIV) or recurrent endometrial cancer: The MITO END-2 trial
    • Lorusso D, Ferrandina G, Colombo N, et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage IIIYIV) or recurrent endometrial cancer: The MITO END-2 trial. J Clin Oncol. 2015;33(suppl):abstract 5502.
    • (2015) J Clin Oncol , vol.33
    • Lorusso, D.1    Ferrandina, G.2    Colombo, N.3
  • 206
    • 84904516125 scopus 로고    scopus 로고
    • Current status ofmolecular biomarkers in endometrial cancer
    • Werner HM, Salvesen HB.Current status ofmolecular biomarkers in endometrial cancer. Curr Oncol Rep. 2014;16:403.
    • (2014) Curr Oncol Rep , vol.16 , pp. 403
    • Werner, H.M.1    Salvesen, H.B.2
  • 207
    • 84865464494 scopus 로고    scopus 로고
    • Molecular targets and targeted therapeutics in endometrial cancer
    • Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24:554-563.
    • (2012) Curr Opin Oncol , vol.24 , pp. 554-563
    • Weigelt, B.1    Banerjee, S.2
  • 208
    • 84953228307 scopus 로고    scopus 로고
    • Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or-nonmutated advanced and/or metastatic endometrial cancer
    • Konecny GE, Finkler N, Garcia AA, et al. Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or-nonmutated advanced and/or metastatic endometrial cancer. Ann Oncol. 2014;25(suppl 4):LBA27.
    • (2014) Ann Oncol , vol.25 , pp. LBA27
    • Konecny, G.E.1    Finkler, N.2    Garcia, A.A.3
  • 209
    • 84893764401 scopus 로고    scopus 로고
    • Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
    • Mackay HJ, Eisenhauer EA, Kamel-Reid S, et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 2014;120:603-610.
    • (2014) Cancer , vol.120 , pp. 603-610
    • MacKay, H.J.1    Eisenhauer, E.A.2    Kamel-Reid, S.3
  • 211
    • 84927154472 scopus 로고    scopus 로고
    • Basket trials and the evolution of clinical trial design in an era of genomic medicine
    • Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33:975-977.
    • (2015) J Clin Oncol , vol.33 , pp. 975-977
    • Redig, A.J.1    Jänne, P.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.